✦ LIBER ✦

Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia

✍ Scribed by Paolo Pedrazzoli; Giovanni Rosti; Simona Secondino; Salvatore Siena

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 102 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24115

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Usage of erythropoiesis-stimulating agen

Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia

✍ Alessandra Ferrajoli; Aman U. Buzdar; Yvette DeJesus; Lee Cheng; Laura B. Michau 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 627 KB

## Abstract ## BACKGROUND: In 2007, the US Food and Drug Administration (FDA) issued regulatory alerts for use of erythropoiesis‐stimulating agents (ESAs) in cancer patients with anemia after clinical trials and meta‐analysis data found that high ESA doses were associated with adverse outcomes in

Thrombocytosis and venous thromboembolis

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron

✍ David H. Henry; Naomi V. Dahl; Michael A. Auerbach 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 776 KB

Expression and function of erythropoieti

Expression and function of erythropoietin receptors in tumors : Implications for the use of erythropoiesis-stimulating agents in cancer patients

✍ Angus M. Sinclair; Marque D. Todd; Kevin Forsythe; Susan J. Knox; Steve Elliott; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB

## Abstract Safety concerns surrounding the use of recombinant human erythropoietin (Epo) to treat anemia in cancer patients were raised after 2 recent clinical studies reported a worse survival outcome in patients who received epoetin α or epoetin β compared with patients who received placebo. Alt

Adriamycin plus alkylating agents in the

Adriamycin plus alkylating agents in the treatment of metastatic breast cancer

✍ Jacob J. Lokich; Arthur T. Skarin; Robert J. Mayer; I. ÀIg Cr Henderson; Ronald 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 2 views

New antimicrobial agents for the treatme

New antimicrobial agents for the treatment of bacterial infections in cancer patients

✍ Kenneth V. I. Rolston 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

## Abstract Patients with cancer develop serious bacterial infections often, especially during periods of severe and prolonged neutropenia. Antibiotic usage for the prevention and treatment of bacterial infections in these high‐risk patients leads to selection pressures resulting in the emergence a

The emerging role of retinoids and retin

The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer

✍ Wilson H. Miller Jr. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

BACKGROUND. Although significant advances have been made in the treatment of some malignancies, the prognosis of patients with metastatic tumors remains poor. Differentiating agents redirect cells toward their normal phenotype and therefore may reverse or suppress evolving malignant lesions or preve